Radiant Biotherapeutics Announces Poster Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
TORONTO & PHILADELPHIA — Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver first-in-class transformative therapies for patients facing life-changing disease, today announced the presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago. The presentation describes the company's Multabody™ platform, a novel approach to stimulating key targets in immunotherapy that have remained out of reach due to toxicity or lack of response.
Article content
Article content
Details on the poster presentation are below:
Article content
Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. Radiant's proprietary Multabody™ platform leverages avidity and multi-specificity, to generate highly efficacious Multabodies with superior potency than other antibody platforms. These powerful Multabodies are a new class of biologics positioned to tackle complex, heterogenous diseases such as cancer, immunology and inflammation, which often have challenging targets and mechanisms. Multabody™ production and manufacturing is flexible, modular and scalable, and leverages standard antibody CMC processes. The groundbreaking efficiency of the platform is driving a novel pipeline of mono-, bi- and tri-specific biologics in multiple therapeutics areas. With offices in Toronto and Philadelphia, Radiant has forged multiple strategic partnerships that validate the Multabody™ platform's broad scientific and clinical utility. For more, visit radiantbio.com.
Article content
Article content
Article content
Contacts
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
11 hours ago
- Cision Canada
G-P Gia Named a 2025 Top HR Product of the Year by HR Executive
G-P's global HR agent recognized as a cutting-edge technology, delivering real-world impact BOSTON, /CNW/ -- REMOTE FIRST COMPANY -- G-P (Globalization Partners), recognized as the undisputed leader in global employment by industry analysts, today announced Global HR Agent G-P Gia™ has been recognized as a Top HR Product of 2025 by HR Executive. The company will be honored on Monday, September 15, 2025, during the inaugural HR Icons Awards Evening at HR Tech 2025, held at Mandalay Bay in Las Vegas. Judges for the 2025 HR Tech Top Product Awards included Elizabeth Clarke, Executive Editor for HR Executive, Jill Barth, HR Tech Editor for HR Executive and Steve Boese, longtime Top Products judge. In Jill Barth's article on HR Executive, she notes that winners such as G-P Gia "showcase the rise of agentic AI in HR. These tools are now handling complex, multi-step processes that once demanded extensive human involvement." HR Executive also noted Gia was recognized for the following: "We think G-P Gia™ offers HR leaders a practical solution for managing global employment complexities. It streamlines tasks like drafting compliant contracts, comparing multi-state policies and handling performance or termination scenarios across jurisdictions. What sets it apart is its integration of proprietary data with legal and HR expertise, enabling real-time, context-aware guidance. We liked that Gia isn't generic but is built on a specialized framework that reduces errors and adapts to local laws, making it especially useful for teams operating across borders. Its ability to generate documents, flag risks and support multilingual interaction helps HR professionals save time and reduce reliance on external legal counsel." G-P Gia is a first-of-its kind agentic AI solution that is transforming global HR. It empowers HR teams to move faster, operate smarter and achieve global ambitions without being held back by the complexities of global employment. Gia is powered by G-P's proprietary knowledge base and vetted by legal and HR experts to deliver real-time, accurate global employment guidance and actionable HR documents for 50 countries and all 50 U.S. states. Gia dramatically reduces reliance on outside counsel and cuts administrative time and fees by up to 95%. "HR isn't just the backbone of every business, it's a strategic driver of growth, and HR teams need sophisticated agentic technology that empowers them to lead," said Nat Natarajan, chief product and strategy officer, G-P. "G-P Gia isn't just another HR tool or generic AI model – it delivers next-level agentic capabilities and deep insights backed by G-P's proprietary data and G-P's verified sources that empower HR organizations to transform global HR and compliance and drive unparalleled business agility and productivity." The annual Top HR Products competition, organized by HR Executive and HR Tech, is designed to showcase a range of notable solutions introduced over the last year. Reviewed by a panel of esteemed judges, each product submission is evaluated based on its level of innovation, value added to the HR function, overall user experience, ability to deliver on its promises and effective integration, customization and analytics capabilities. The full list of the 2025 award-winning products can be viewed here. Attendees of HR Tech 2025 can learn more about G-P and G-P Gia by visiting Booth No. #4633. About HR Executive Established in 1987, HR Executive is the premier global media company covering strategic issues in HR. Part of the Arc network, HR Executive provides more than 220,000 subscribers with news, content and analysis of global HR trends. HR Executive is where HR professionals go when they need to know, providing in-depth coverage on all facets of human resource management, including recruiting, talent acquisition, compensation and benefits, learning and development, employment law, talent management, the latest technologies and more. Visit About HR Tech HR Tech is the industry's premier event series showcasing breakthrough HR technologies, with its flagship U.S. conference serving as its cornerstone since 1997. HR Tech in the U.S. features the world's largest expo of innovative HR solutions, live product demonstrations and the industry's preeminent startup competition. The HR Tech portfolio has expanded globally with additional annual events in Europe and Asia, creating a worldwide network of innovation hubs that shape the future of work. HR Tech is part of the event arm of HR Executive, a prestigious global media company established in 1987 that delivers news, content and analysis of strategic HR trends to more than 220,000 subscribers worldwide. The synergy between the events and media channels enables the brands to create a comprehensive knowledge ecosystem that addresses all aspects of human resource management, establishing the organization as the definitive authority for visionary HR leaders. Visit to learn more. About G-P G-P (Globalization Partners) is the recognized leader in global employment, ranked No. 1 in every industry analyst report. G-P's global employment platform delivers everything companies of all sizes need to manage the full employee lifecycle with its trusted Global HR Agent, G-P Gia, and AI-powered Employer of Record (EOR) and Contractor products. G-P supports teams in 180+ countries with more than a decade of global employment experience, the largest team of in-country HR, legal, and compliance experts, and its unmatched proprietary knowledge base.
Toronto Star
12 hours ago
- Toronto Star
PharmaTher Announces FDA Approval of Ketamine (KETARx™)
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the 'Company' or 'PharmaTher') (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved the Company's ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achievement for PharmaTher and strategically positions the Company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards mental health, neurological, and pain disorders.
Cision Canada
18 hours ago
- Cision Canada
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXia293 Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293 Stable platform maintains stable expression and consistent product quality during long-term cell passages, enabling scalable clinical and commercial manufacturing. SHANGHAI, Aug. 11, 2025 /CNW/ -- WuXi Biologics ( a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable, a new platform designed for the development and manufacturing of innovative, difficult-to-express molecules that are stably expressed in HEK293 cells. The platform, which demonstrates high titers, robust stability and superior quality, significantly enhances the developability and manufacturability of these molecules, offering a highly efficient CMC solution for biologics that are sophisticated in both structure and function. Conventionally, CHO cells have been widely utilized for recombinant protein expression with proven track record of high titers, and good developability and manufacturability. However, complex modalities may not be compatible with CHO expression system, resulting in low titer levels and truncation issues, due to the impact of some CHO-specific host cell proteins (HCPs), that compromise the quality and functionality of the protein products. In contrast, HEK293 cells can eliminate or significantly alleviate truncation issues in expressing complex molecules while maintaining high titer levels. WuXi Biologics developed WuXia293 Stable by leveraging its proprietary HEK293 cell line. Derived from WuXi Biologics' highly-vetted mammalian cell line development platform family WuXia™, WuXia293 Stable demonstrates productivity, quality and stability comparable to WuXia™ while maintaining full compatibility with its process, as shown by its robust growth and balanced metabolism. The platform achieves a fed-batch titer of up to 5.0 g/L for monoclonal antibodies while significantly improving purity. WuXia293 Stable offers flexible scalability in culture scale to meet the diverse needs of various research and pre-clinical development stages. Furthermore, the WuXia293 Stable cell line maintains stable expression and consistent quality during long-term cell passages, enabling scalable clinical and commercial manufacturing at 2000L scale for fed-batch and 1000L scale for perfusion. Moreover, WuXi Biologics offers a comprehensive suite of services for the WuXia293 Stable platform, including cell bank testing and viral clearance validation as part of its one-stop CMC solution. The launch of the WuXia293 Stable platform has further strengthened the service capabilities of WuXi Biologics' WuXia™ platform family. Besides WuXia293 stable, the WuXia™ platform has already derived multiple cell line development platforms, including WuXia ADCC Plus™ and WuXia RidGS™, to address customers' diverse requirements. Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are excited to launch an industry-leading solution that significantly enhances the development of advanced therapeutics. WuXia293 Stable stands as a powerful testament to WuXi Biologics' unwavering commitment to our vision that every biologic can be made and exemplifies our dedication to technological innovation, which enables us to adeptly address the evolving needs of the biopharmaceutical industry. Once again we are reaffirming our promise to enable our clients in accelerating the delivery of innovative biologics to patients worldwide. " About the WuXia™ Cell Line Development Platform Family WuXia™ is a proven, high-yield (up to about 11 g/L) mammalian cell line platform family developed by WuXi Biologics. Accepted by regulatory agencies worldwide, the WuXia™ platform family have generated over 1000 cell lines expressing monoclonal and bispecific antibodies, fusion proteins, enzymes and other recombinant proteins for clinical and commercial manufacturing as of 2024. The WuXia™ platform family include WuXia ADCC Plus™ for developing and manufacturing afucosylated antibodies to elicit an enhanced ADCC response, WuXia RidGS™ for non-antibiotic cell line development, and the latest WuXia293 Stable for expressing difficult-to-express molecules built on HEK293 cell lines. The WuXia™ cell line development platform family continue to expand to cater to the diverse needs of global customers.
